Squalamine - Ohr Pharmaceutical

Drug Profile

Squalamine - Ohr Pharmaceutical

Alternative Names: EVIZON; MSI-1256F; OHR 102; Squalamine lactate

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genaera Corporation
  • Developer Genaera Corporation; Ohr Pharmaceutical
  • Class Antineoplastics; Cholestanols; Eye disorder therapies; Lactates; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase II Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion
  • Discontinued Fibrodysplasia ossificans progressiva; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 05 Jan 2018 Top-line efficacy data from the phase III MAKO trial in Wet age-related macular degeneration released by Ohr Pharmaceutical
  • 25 Apr 2017 Ohr Pharmaceutical withdraws a phase II trial prior to enrolment due to a company decision in Wet age-related macular degeneration (Combination therapy, In adults, In the elderly) in USA (Ophthalmic) (NCT02511613)
  • 14 Feb 2017 Ohr Pharmaceutical suspended enrolment in the phase III trial for Wet age-related macular degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top